ANNUAL REPORT 2002
|
|
|
|
|
 |
|
|
The purpose of intravenous oxygen-carrying support is to help stabilize the patient and prevent tissue damage or organ
dysfunction associated with oxygen deprivation. When Hemopure or Oxyglobin is infused into the bloodstream, its chemically
stabilized hemoglobin molecules carry oxygen in the plasma (the fluid part of blood) and facilitate the release of oxygen
from red blood cells, increasing diffusion of oxygen to tissues. If necessary, this effect can be extended over time by
repeat dosing to provide a continuous Oxygen Bridge until anemic patients can recover. Since treatment protocols for
managing patients' oxygen requirements are historically based on the use of blood, our challenge at Biopure is to educate
medical providers on the unique physiology of Hemopure and how to use the Oxygen Bridge approach
to achieve better treatment regimens and patient outcomes.
|
|
|
 |
|
|
"We've found Hemopure to be very effective and safe to use in two Phase III surgery trials and in post-approval use in South Africa. We continue
to utilize it for postoperative anemia, and envision utilizing it in the future in other conditions where tissue hypoxia plays a major
pathophysiological role."
R. Van Rooyen, M.D.
Pretoria Heart Hospital, South Africa
|
|
|
|
|